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Altered proliferative responses of dermal
fibroblasts to TGF-1 may contribute to chronic
venous stasis ulcer
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Joaquim J. Cerveira, MD,a,c Robert W. Hobson II, MD,a,b and Walter N. Durán, PhD,a,b Newark
and East Orange, NJ
Purpose: Venous ulcer fibroblasts demonstrate decreased proliferative responses to growth factor stimulation, suggesting
cellular senescence. However, the role of chronic venous insufficiency (CVI) disease progression and extracellular matrix
(ECM) proteins in agonist-induced cellular proliferation is ill-defined. We hypothesize that CVI-induced fibroblast
proliferative resistance to growth factors worsens with disease progression and is regulated by the composition of ECM.
Methods: Fibroblast explants were isolated from biopsy specimens from two patients without CVI and 16 patients with
CVI of the lower calf (LC) and lower thigh (LT) and stratified according to CEAP disease severity: non-CVI (NC; n 
2), class 2-3 (n 5), class 4 (n 5), class 5 (n 3), and class 6 (n 3). Proliferation experiments were standardized with
a neonatal foreskin fibroblast cell line (HS68). A 10-day course and dose response experiment with 0, 0.5, 1.0, 2.5, 5, 10,
and 20 ng/mL of transforming growth factor-1 (TGF-1) demonstrated maximal cell proliferation at 5 ng/mL of
TGF-1 on day 4. Under these conditions, CVI dermal fibroblasts were challenged with and without TGF-1 and
evaluated for proliferative responses on plates coated with polystyrene, collagen, and fibronectin.
Results: No differences in unstimulated proliferation were observed in LT and LC fibroblasts from patients with class 2-3
disease and LT fibroblasts from patients with class 4 and 5 disease, compared with NC and HS68 cells. LC fibroblasts
from patients with class 4 disease (P < .05) and class 5 disease (P < .001), and LC (P < .001), and LT fibroblasts from
patients with class 6 disease (P < .001) proliferated to a lesser degree than did NC and HS68 cells. The diminished
proliferation observed in class 4 LC cells was reversible with TGF-1 stimulation (P < .004); however, class 5 and class
6 LC and LT fibroblasts did not respond to stimulation with TGF-1. Collagen increased proliferation of HS68 cells with
(P < .05) and without (P < .01) TGF-1, compared with cells grown on polystyrene, but did not increase proliferative
responses in NC or CVI fibroblasts with and without TGF-1. Similarly, fibronectin increased proliferation of HS68 cells
(P < .05) compared with cells grown on polystyrene, but did not alter proliferation in CVI fibroblasts. Fibronectin did
seem to inhibit TGF-1-induced proliferation observed in class 4 LC cells.
Conclusion: These data indicate that clinical disease progression correlates with cellular dysfunction. Fibroblasts from
patients with class 2-3 disease retain their unstimulated and agonist- induced proliferative capacity, compared with NC
and HS68 cells. The onset of inflammatory skin changes (class 4 and class 5 disease) diminishes agonist-induced
proliferation, and ulcer formation (class 6 disease) severely inhibits it. In addition, the composition of ECM does not
affect TGF-1-induced proliferation of fibroblasts in CVI. (J Vasc Surg 2003;37:1285-93.)
Lack of animal models that mimic the dermal sequelae
of persistent chronic venous hypertension has resulted in a
paucity of information regarding the signaling events that
regulate chronic venous insufficiency (CVI)-associated der-
mal skin conditions. Venous hypertension results in extrav-
asation of red blood cells and macromolecules such as
fibrinogen and 2-macroglobulin into the dermal intersti-
tium of patients with CVI.1 These cells and molecules are a
chronic injury stimulus, resulting in inflammatory leuko-
cyte recruitment and microcirculatory activation. When
leukocytes enter the dermal interstitium, transforming
growth factor-1 (TGF-1) and matrix metalloproteinases
(MMPs) are released in response to these inflammatory
mediators.2,3 Increased TGF-1 activity is associated with
CVI disease progression and dermal skin conditions, and
fibroblasts are the target cells of leukocyte- derived
TGF1.
2,4
Fibroblasts are activated and proliferate when cultured
on polystyrene plates containing growth media with serum.
Fibroblast proliferative responses are important in wound
healing and fibrogenic pathologic conditions such as sys-
temic sclerosis.5 Although several cytokines have been im-
plicated in disease states associated with fibroblast prolifer-
ation, eg, interleukin-1 (IL-1), tumor necrosis factor-,
platelet-derived growth factor, and fibroblast growth fac-
tor, the most potent mediator of cellular proliferation and
extracellular matrix (ECM) production is TGF-1.
6,7
TGF-s are a large superfamily of soluble factors important
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in growth, development, and fibroblast proliferation.
TGF-1 is the isoform usually upregulated in the presence
of tissue injury and is the primary mitogenic signal for
fibroblasts in wound healing.5
ECM is a complex structure of several collagenous and
noncollagenous proteins that provides a scaffold for inter-
cellular and intracellular interactions. These interactions are
regulated by contact of matrix proteins (integrins) with
their corresponding integrin receptors.8 ECM proteins
alone and in conjunction with growth factors can regulate
fibroblast proliferation.8,9 For example, TGF-1-induced
fibroblast proliferation is augmented by the ED-A domain
of fibronectin in a dose-dependent manner.10 In addition,
fibronectin reverses G1 arrest in previously unresponsive
fibroblasts.9 The role of ECM proteins and TGF-1 on
CVI fibroblast proliferation is ill-defined. We previously
demonstrated that CVI disease progression is associated
with increased tissue levels of active TGF-1. In addition,
CVI fibroblasts derived from venous ulcer explants demon-
strate diminished proliferation.11-13 We therefore hypoth-
esized that TGF-1-induced fibroblast proliferative re-
sponses in CVI are regulated by the composition of ECM
and are altered with disease progression.
METHODS
Patient selection and disease severity classification.
Sixteen patients with CVI were included in the study. To
ensure that the observed measurements were secondary to
CVI alone, patients were excluded if they had active infec-
tion, cancer, rheumatoid arthritis, vasculitis, or collagen
vascular disease; had undergone surgery within 6 weeks;
used steroid medications; or had a history of or current use
of intravenous drugs. Two patients without CVI were also
included in the study as non-CVI (NC) controls. Informed
consent was obtained from each patient, and the research
protocol was approved by the institutional review boards of
UMDNJ-New Jersey Medical School and the East Orange
Veterans Affairs Medical Center.
All patients with CVI and control subjects without CVI
underwent venous duplex scanning with a 5 MHz imag-
ing/5 MHz pulsed-wave Doppler color-flow system
(Quantum 2000; Siemens, Seattle, Wash) to confirm the
presence or absence of venous reflux and extent of disease.
In addition, the site of valvular incompetence, pattern of
reflux, and location of chronic venous obstruction in deep
and superficial systems were also determined.14 Most pa-
tients had bilateral lower extremity venous disease, and
assignment to a clinical group was based on the more
severely affected limb.
Punch biopsy specimens were obtained from the af-
fected lower calf (LC; disease samples) and from the lower
thigh (LT) of 16 patients (internal control subjects). One
biopsy specimen each was acquired from the lower thigh of
2 subjects without CVI (NC control samples) who were
undergoing bypass procedures because of arterial insuffi-
ciency. Biopsy specimens were stratified according to The
American Association for Vascular Surgery/Society for
Vascular Surgery (AAVS/SVS) CEAP disease classification
for CVI15: NC (n 2), class 2 or 3 (n 5), class 4 (n 5),
class 5 (n  3), or class 6 (n  3).
Biopsy protocol. Biopsy specimens were obtained as
described.4 In brief, after injection of 1% lidocaine, two 6.0
mm punch biopsy samples were obtained from areas that
demonstrated clinical signs of venous stasis dermatitis in the
LC and two from clinically normal skin in the ipsilateral LT.
Biopsy sites were closed with single 2-0 prolene sutures,
and dressings were applied. Sutures were removed at
1-week follow-up assessment of the wound. In patients
undergoing vein stripping or perforator ligation, biopsy
tissue was obtained from incision sites made during sur-
gery. Thigh biopsy specimens from clinically normal skin,
obtained from patients undergoing infrainguinal revascu-
larization surgery, served as NC controls. Calf biopsy sam-
ples were not obtained from this group because of the
possibility of inducing wound complications.
Primary fibroblast culture protocol. Dermal fibro-
blasts were isolated from explanted biopsy specimens. Skin
biopsy tissue was processed immediately after harvesting.
Subcutaneous fat and epidermis were excised, and explants
were cut into approximately 1 mm3 pieces. Tissue explants
were disinfected with three sequential washes with full-
strength povidone iodine (5 minutes), 70% ethanol (5
minutes), and 250 g/mL of amphotericin-B (10 min-
utes). The interstitial and remaining epidermal elements
were digested with 0.25% trypsin at 4°C 18 hours, followed
by 30 minutes of digestion at 37oC. The explants were then
seeded onto 60 mm etched culture plates and cultured with
Dulbecco’s modified Eagle’s media (DMEM) containing
10% fetal bovine serum (FBS), 1% penicillin-streptomycin,
and 1 g/mL of amphotericin-B (all culture media from
Gibco BRL, Rockville, Md). The media were first changed
at week 1 and every 2 days thereafter. Most explants dem-
onstrated growth of fibroblasts within 2 weeks (Fig 1), at
which point explants were removed. Cells were trypsinized
at 50% to 70% confluence. Half of the cells were frozen in
dimethyl sulfoxide solution in liquid nitrogen for future
use. The remaining cells were replated and used for prolif-
eration experiments. All experiments were performed on
passage 3 or less cells.
Time course and dose response of fibroblasts to
TGF-1. The optimal dose and time for TGF-1-induced
proliferative responses of fibroblasts were standardized with
a commercially available neonatal foreskin fibroblast cell
line (HS68; American Type Culture Collection, Rockville,
Md). HS68 cells from passages 2 to 5 were seeded into
24-well polystyrene plates at a density of 15,000 cells per
well. The cells were serum starved for 18 hours with
DMEM alone, then cultured in DMEM containing 10%
FBS with or without TGF-1 (Sigma, St Louis, Mo). The
cells were then trypsinized and stained with trypan blue to
determine viability, and were manually counted with a
hemocytometer. These measurements were performed
daily for 10 days. Linear regression analysis was performed
to determine logarithmic cell growth period for fibroblasts
stimulated with TGF-1. The experiment was repeated in a
representative sample of fibroblasts derived from a patient
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with CVI to confirm that adult fibroblasts followed the
same proliferation kinetics as the neonatal cells did.
Once the logarithmic period had been determined,
HS68 cells were exposed to increasing doses of TGF-1
(0.5, 2.5, 5, 10, and 20 ng/mL) in a separate experiment.
Cell count and viability assessments were performed for
each dose during the logarithmic period of growth to
determine the dose responsible for maximal TGF-1-in-
duced proliferation.
Proliferative response of patient fibroblasts. Pri-
mary cultures from 16 patients with CVI patients, 2 pa-
tients without CVI, and HS68 cells were then subjected to
the following experiments. Fibroblasts were seeded into
24-well plates at a density of 15,000 cells per well. Cells
were cultured with and without TGF-1 and counted
during the logarithmic period, as determined in the previ-
ous experiments. All experiments were first performed with
patient fibroblasts growing on polystyrene 24-well plates
without TGF-1 to determine baseline unstimulated pro-
liferation. The proliferative response to TGF-1 was subse-
quently evaluated. Patient fibroblasts were then seeded
onto 24-well plates coated with type I collagen (BioCoat;
Becton Dickinson, Franklin Lakes, NJ) and fibronectin
(BioCoat) with and without TGF-1, and proliferative
responses were measured.
Statistical analysis. A minimum of four wells per ex-
plant were tested under each condition. Differences in
mean SEM between groups were analyzed with one-way
analysis of variance and the Bonferroni post hoc test. Dif-
ferences within groups were analyzed with a two-tailed
unpaired t test. Significance was accepted at P  .05. All
statistical analyses were performed with GraphPad Prism
(version 3.00; GraphPad Software, San Diego, Calif).
RESULTS
Patient demographics. Thirteen men and 5 women
were enrolled in the study. Their mean age was as follows:
NC control subjects, 54 years (range, 50-58 years); patients
with class 2-3 disease, 35.2 years (range, 20-54 years);
patients with class 4 disease, 57.4 years (range, 37-71
years); patients with class 5 disease, 58.6 years (range,
38-80 years); and patients with class 6 disease, 53.9 years
(range, 50-82 years). Associated medical comorbid condi-
tions are presented in Table I. The clinical, etiologic, ana-
tomic, and pathophysiologic distribution of CVI was deter-
mined clinically and with duplex ultrasonographic (US)
scanning as per the recommended reporting standards of
the AAVS/SVS. The distribution of reflux on duplex US
scans is summarized in Table II. Post-phlebitic vein wall
changes were not noted in any patients.
Proliferation kinetics. Unstimulated neonatal fibro-
blasts (HS68) proliferated on polystyrene plates, and the
rate was significantly increased when challenged with 5
ng/mL of TGF-1 (P  .05). Linear regression analysis of
Fig 1. Dermal fibroblasts were cultured from lower extremity skin biopsy specimens (see Methods). In 2 to 3 weeks,
patient fibroblasts could be seen migrating from the explant and populating the culture dish.
Table I. Associated medical comorbid conditions
Patients without
CVI (n  2)
Patients with CVI
(n  16)
Diabetes 0 0
Stroke 0 1
Coronary artery disease 1 1
Hypertension 1 3
Tobacco use 2 7
COPD 0 0
Deep vein thrombosis 0 0
CVI, Chronic venous insufficiency; COPD, chronic obstructive pulmonary
disease.
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the growth curve demonstrated logarithmic cell growth
between days 2 and 7 (Fig 2, A). The proliferation kinetics
of a primary fibroblast culture from a patient with CVI
CEAP class 6 was studied. We chose CEAP 6 patient
fibroblasts because they could be expected to have the
slowest rate of proliferation and therefore significantly dif-
ferent growth kinetics. This study would enable us to
identify the appropriate time in the mid-logarithmic phase
to conduct future experiments. The growth curve of the
CEAP 6 cells demonstrated a similar logarithmic phase
between days 2 and 7, although with a significantly lower
slope than that of HS68 cells (P  .05; Fig 2, B). Prolifer-
ation counts were therefore performed on day 4, in mid-
logarithmic phase, for all further experiments.
Dose response. HS68 fibroblasts were grown in the
presence of increasing concentrations of TGF-1, and pro-
liferation was assessed on day 4. Proliferation was maximal
at a dose of 5 ng/mL (P .05; Fig 3). TGF-1 concentra-
tions of 0.5 and 20 ng/mL did not cause increased prolif-
eration. TGF-1 at 5 ng/mL was used for all further
proliferation experiments.
Baseline unstimulated proliferation of patient fi-
broblasts according to disease severity. HS68, NC, and
CVI fibroblasts were grown on polystyrene plates, and cell
counts were performed on day 4 (Fig 4). Percent cell
viability was noted to be greater than 95% in all cases. NC
fibroblasts proliferated to the same degree as HS68 cells
under these baseline conditions (P  .05). Similarly, LT
and LC fibroblasts from patients with CEAP 2-3 CVI and
LT fibroblasts from patients with CEAP 4 and 5 CVI
proliferated as well as did NC and HS68 cells (P .05 in all
instances). However, LC fibroblasts from patients with
CEAP 4 CVI demonstrated significantly lower proliferation
(P .0 1 vs HS68, and P .001 vs LT cells of same class).
Similarly, LC fibroblasts from patients with CEAP 5 CVI
proliferated less than did HS68 cells (P .05) and their LT
counterparts (P  .01). Conversely, both, LT and LC
fibroblasts from patients with CEAP 6 CVI proliferated to
a lesser degree (vs HS68 cells, P .001 for both; and vs NC
cells, P  .001 for both).
Proliferation response to TGF-1 according to dis-
ease severity. HS68, NC, and CVI fibroblasts were grown
on polystyrene plates, and their response to 5 ng/mL of
TGF-1 stimulation was assessed (Fig 5). HS68 cells dem-
onstrated increased proliferation with TGF-1 above their
unstimulated baseline value (P  .05). NC cells demon-
strated a trend toward increased proliferation with TGF-1
but did not reach statistical significance. Both LT and LC
fibroblasts from CEAP 2-3 CVI demonstrated increased
proliferation with TGF-1 compared with their unstimu-
lated baseline value (P  .0 5 for both). Of note, LC
fibroblasts from CEAP 4 CVI demonstrated increased pro-
liferation with TGF-1 (P  .05) compared with unstimu-
lated CEAP 4 CVI cells. LT and LC fibroblasts from
patients with CEAP 5 disease did not demonstrate in-
creased proliferation in response to TGF-1 compared with
their respective unstimulated baseline value. CEAP 6 LT
and LC fibroblasts demonstrated significantly diminished
unstimulated proliferation at baseline compared with both
HS68 and NC cells, and proliferation did not increase in
response to TGF-1 stimulation.
Proliferation response to collagen and fibronectin.
HS68, NC, and CVI fibroblasts were grown on plates
coated with polystyrene, type I collagen, and fibronectin
with and without TGF-1 stimulation, and cell counts were
performed on day 4. Unstimulated HS68 fibroblasts (Fig 6,
A) demonstrated increased proliferation when grown on
collagen (P  .01) and fibronectin (P  .001) compared
with polystyrene. However, proliferation of NC fibroblasts
was not increased with either ECM protein. Similarly,
proliferation of LC and LT fibroblasts from any CVI class
was not increased in the presence of ECM proteins when
compared with polystyrene.
TGF-1 stimulation (Fig 6, B) increased proliferation
of HS68, NC, and CEAP 2-3 LT and LC fibroblasts above
their respective unstimulated baseline value. However, no
synergistic or additive proliferative responses were observed
when these experiments were repeated with cells grown on
ECM proteins (collagen or fibronectin). CEAP 5 and 6 LT
and LC fibroblasts stimulated with TGF-1 exhibited no
increase in proliferation compared with their respective
unstimulated baseline value whether cultured on polysty-
rene, collagen, or fibronectin. ECM proteins did not seem
to alter the response of patient fibroblasts to TGF-1 when
compared with cells grown on polystyrene. The only excep-
tion to this trend was LC fibroblasts from patients with
CEAP 4 disease. These cells did not proliferate in response
to TGF-1 in the presence of fibronectin compared with
polystyrene (P  .05).
DISCUSSION
CVI disease progression is characterized by an intense
leukocyte inflammatory response, ECM deposition,
changes in cellular architecture, and tissue fibrosis indicat-
ing an imbalance between tissue degradation and re-
pair.15-18 In CVI, fibroblasts are central to the processes
described above.5,6,17 They are the target cells of leuko-
cyte-derived TGF-1, principal producers of ECM pro-
teins, and are intimately involved in wound contraction and
healing.5,11
Of the known cytokines, TGF-1 is the prototypical
regulator of fibroblast activation and proliferation.5-7,19 In
patients with CVI the source of TGF-1 seems to be dermal
leukocytes, with interstitial collagen matrix serving as an
important repository of latent TGF-1.
4,20 We previously
demonstrated a correlation between local dermal TGF-1
Table II. Description of reflux with duplex scanning
Class 2-3 Class 4 Class 5 Class 6
Superficial 2 2 0 0
Superficial, deep 0 0 1 1
Superficial, perforator 2 2 2 1
Superficial, deep, perforator 1 0 1 1
Postphlebotic 0 0 0 0
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tissue levels and CVI disease progression.2 Increasing pro-
tein concentrations of active TGF-1 were noted in dermal
biopsy specimens with increasing CEAP severity of disease
(healthy skin, 1.0 ng/g; class 4, 5.01 ng/g; class 5, 8.3
ng/g; and class 6, 5.4 ng/g).2 The biologic activity of
TGF-1 is closely controlled by its concentration. Femto-
molar concentrations are strongly chemotactic for leuko-
cytes and fibroblasts, whereas low nanomolar concentra-
tions activate monocytes and fibroblasts. In addition, high
nanomolar concentrations may inhibit fibroblast activation
and proliferation. The mechanism of this concentration
effect on cellular proliferation has not been determined. In
the present study, we systematically performed a dose-
response and time course experiment with TGF-1 on
fibroblasts and found that the maximal in vitro proliferative
response to TGF-1 occurs at the same concentrations
present in the tissues of patients with advanced CVI. This
observation suggests that tissue concentrations of TGF-1
observed in severe CVI (CEAP 4-6) could induce signifi-
cant fibroblast proliferative responses.
The “dual control model of proliferation” suggests that
optimal cellular replication requires the presence of a
Fig 2. Logarithmic growth phase kinetics. Proliferation response of fibroblasts to 5 ng/mL of TGF-1 over 10 days.
A, Response of HS68 fibroblasts. B, Response of fibroblasts from a patient with CEAP class 6 CVI. On linear regression
analysis the logarithmic period of growth extended from days 2 to 7 in both cases.
Fig 3. Dose response. Proliferation response of HS68 fibroblasts to increasing concentrations of TGF-1. Fibroblasts
responded with increased proliferation at TGF-1 concentrations of 2.5 ng/mL (P .05), 5 ng/mL (P .001), and
10 ng/mL (P  .01).
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growth factor as well as a coactivator. Recent investigations
have demonstrated that, in the case of fibroblasts, ECM can
function as a coactivator.9,21 In the presence of a fixed dose
of TGF-1, both collagen and fibronectin stimulate fibro-
blast replication in a dose-dependent manner.9,10,21 Signal-
ing between ECM and fibroblasts occurs through integrin
receptor stimulation at the surface of the cell (collagen,
mainly 11 and 21; fibronectin, mainly 31).
11 Clini-
cally and histologically, intense ECM deposition has been
observed in the lower extremities of patients with CVI,
suggesting a coactivator role for these proteins in CVI
disease progression.4,22 We anticipated that excessive
TGF-1 tissue levels, in conjunction with increased ECM
proteins, would result in increased CVI fibroblast prolifer-
ation.2,6 However, several reports have noted that fibro-
blasts cultured from CVI ulcer edge explants demonstrate
diminished baseline and agonist- induced proliferative re-
sponses.7 These investigations have suggested that cellular
senescence is a possible cause for these observations12,13;
however, the cytochemical component responsible for
these phenotypic alterations in CVI fibroblasts remains
unknown. Similarly, the relationship of these proliferation
abnormalities to CEAP disease severity is ill-defined.
Fibroblasts cultured from patients with early manifes-
tations of CVI (CEAP class 2-3) and LT fibroblasts from
patients with class 4 and 5 CVI proliferated to the same
extent as did HS68 and NC fibroblasts under baseline
conditions. However, fibroblasts from areas of clinically
evident disease (LC) in class 4 and 5 CVI demonstrated
reduced baseline proliferation, as did class 6 fibroblasts
from both LT and LC explants. We therefore observed
progressive worsening of baseline proliferation with disease
progression: normal proliferation in class 2-3; regional
variation between LT and LC in class 4 and class 5 disease;
and proliferative deficiency throughout the entire lower
extremity, not limited solely to the ulcer edge, in class 6
disease.
When stimulated with 5 ng/mL of TGF-1, neonatal
foreskin and class 2-3 fibroblasts demonstrated significantly
increased proliferative responses above their respective
baseline value. It is clear that fibroblasts in this stage of
disease retain their ability to respond to mitogenic stimuli.
There was a trend toward proliferation of NC fibroblasts
exposed to TGF-1 above their unstimulated baseline
value, but the result was not statistically significant. This is
probably related to the limited number of patients in this
group; more subjects in this group could potentially
strengthen the conclusions. Of note, TGF-1 treatment
resulted in the rescue of fibroblasts derived from the LC in
patients with class 4 CVI. These cells demonstrated signif-
icantly increased proliferation above their baseline value
after treatment with TGF-1. This was the only group of
fibroblasts that demonstrated a rescue response unlike that
of class 5 and 6 LT or LC cells. Our results demonstrate
that proliferative resistance to TGF-1 characterizes class 5
and 6 fibroblasts, of which patients with class 6 CVI are
most severely affected. Furthermore, this proliferative resis-
tance may not be limited to regions of clinically active
disease, indicating a more global proliferative defect.
Progressive loss of proliferative capacity in patients with
venous ulcer may also explain why trials with direct appli-
cation of TGF-1 to CVI-associated ulcers have failed to
substantially accelerate healing.23,24 One group has studied
agonist-induced proliferation of fibroblasts cultured from
CVI ulcer edges and noted variable results. Proliferation
was augmented by basic fibroblast growth factor and epi-
dermal growth factor in most but not all fibroblast cultures.
IL-1 had no effect on proliferation. Although these cyto-
kines are mitogenic to fibroblasts, they are not the primary
agonists for fibroblast activation and proliferation, and their
protein expression has not been reported to be altered in
CVI affected limbs. Trials using local application of these
growth factors for CVI ulcer healing have resulted in mar-
ginal success at best.25,26
Although progressive proliferative resistance to
TGF-1 may explain the low baseline proliferation of class 4
to class 6 CVI, the mechanism for this resistance remains
unknown. Since fibronectin and type I collagen are ex-
pressed in abundance during different stages of wound
healing and granulation tissue formation, we tested the
hypothesis that ECM proteins may modulate the prolifer-
ative action of TGF-1 on CVI fibroblasts. In the absence
of TGF-1, collagen increased baseline proliferation of
neonatal fibroblasts but not of fibroblasts isolated from
adults with NC or patients with CVI. TGF-1 stimulation
in the presence of collagen did not result in additional
proliferation of neonatal or patient fibroblasts beyond that
seen with TGF-1 on polystyrene, indicating that collagen
matrices in these experimental conditions did not augment
Fig 4. Baseline unstimulated proliferation of fibroblasts derived
from HS68 cell line, NC skin, and patients with CVI. LT and LC
fibroblasts from patients with CEAP 2-3 disease demonstrated
proliferation similar to that of HS68 and NC adult skin fibroblasts.
CEAP 4 LC fibroblasts proliferated less compared with LT cells
(*P  .001) and HS68 cells (P  .05). LC CEAP 5 fibroblasts
proliferated less than LT cells did (P  .001). LC fibroblasts
from patients with CEAP 4 and 5 CVI proliferated to the same
degree as HS68 did. However, both LT and LC fibroblasts from
CEAP 6 CVI proliferated less than did HS68 and NC adult skin
cells (#P  .001 for both).
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the mitogenic action of TGF-1 on patient fibroblasts
grown as a monolayer. Although most studies addressing
fibroblast proliferation have been conducted in vitro with
monolayer cultures, in vivo skin fibroblasts are surrounded
by dermal ECM proteins in a three-dimensional (3D)
arrangement. To study fibroblast behavior in a situation
resembling the in vivo environment more closely, experi-
ments have been conducted with 3D collagen matrix gels.
Investigations with fibroblasts isolated from hypertrophic
scars27 demonstrated that dermal fibroblasts can reorganize
collagen matrix to cause contraction. The subsequent ten-
sion within the matrix causes substantial fibroblast prolifer-
ation. This mechanism may be involved in the genesis of
hypertrophic scars occurring at flexural surfaces of high skin
tension.28 Conversely, the mechanism for an observed in-
crease in proliferation of fibroblasts in scleroderma29 ap-
pears to be upregulation in the number of TGF-1 recep-
tors on the cell surface. These cells do not demonstrate
increased proliferation within 3D collagen gels compared
with monolayers grown on collagen. In the current study,
TGF-1 in conjunction with collagen did not result in
additive or synergistic increases in fibroblast proliferation.
Possible causes of this phenomenon are need for a 3D ECM
configuration, downregulation of TGF-1 type I or II
receptors in CVI, and altered integrin receptor signaling in
CVI.
Like collagen, fibronectin can serve as a fibroblast
growth factor and coactivator of fibroblast proliferation in
conjunction with other growth factors.9 Both intact fi-
bronectin molecules and their fragments demonstrate func-
tional activity.30 Fibronectin may contribute to transforma-
tion of vascular smooth muscle cells from a contractile to a
proliferative phenotype in conditions such as atherosclero-
sis, restenosis, and hypertension.31,32 The end organ dam-
age seen in the heart in hypertension is characterized by a
marked increase in fibronectin expression and smooth mus-
cle cell proliferation.31,32 Tissue injury can give rise to
several splice variants of fibronectin, of which the ED-A
isoform promotes fibroblast proliferation in granulation
tissue, cirrhosis, pulmonary fibrosis, and other fibrogenic
diseases.32 In this study, fibronectin functioned as a growth
factor for neonatal fibroblasts. The proliferation of non-
CVI adult cells and patient fibroblasts across all disease
classes, however, remained unchanged from their respec-
tive baseline value. On stimulation with TGF-1, LC fibro-
blasts from patients with class 4 disease that had previously
been rescued by TGF-1 failed to exhibit increased prolif-
eration. This result may be of possible significance, but
there was no consistent trend among other classes of fibro-
blasts. The absence of a permissive or promoter role of
fibronectin in CVI could be secondary to culturing cells
under monolayer conditions. Alternatively, the appropriate
fibronectin splice variant that promotes proliferation may
not have been present in our monolayer culture system or
actively degraded in CVI-affected tissue.
In summary, our data indicate that clinical disease
progression correlates with cellular dysfunction. Baseline
proliferation of fibroblasts in patients with CVI progres-
sively diminishes with increasing disease severity. ECM
does not appear to augment agonist-induced cellular pro-
liferation. The cause of CVI fibroblast proliferative resis-
tance remains unknown. Therapeutic methods to acceler-
ate ulcer healing in patients with CVI will benefit
Fig 5. Proliferation response to TGF-1 (5 ng/mL) of fibroblasts derived from HS68 cell line, NC skin, and patients
with CVI. HS68 cells (*P  .001), LT fibroblasts (#P  .001), and LC fibroblasts (P  .007) from patients with
CEAP 2-3 CVI and LC fibroblasts (P  .004) from patients with CEAP 4 CVI all demonstrated increased
proliferation when exposed to TGF-1. However, LC and LT fibroblasts from patients with CEAP 5 and 6 CVI did not
exhibit increased proliferation in response to TGF-1.
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substantially from additional information regarding mech-
anisms that regulate proliferative resistance of fibroblasts.
Supported in part by the American Venous Forum-
JOBST Grant 2001-2002.
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